An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy weight men: a randomised, cross-over clinical trial - Walker, Edward G; Lo, Kim R; Pahl, Malcolm C; Shin, Hyun Sang; Lang, Claudia; Wohlers, Mark W; Poppitt, Sally D; Sutton, Kevin H; Ingram, John R (medRxiv, 2021)
Background Gastrointestinal enteroendocrine cells express a range of chemosensory receptors involved in detecting the chemical composition of food during digestion. These receptors, including bitter taste receptors (T2Rs), may play an important role in regulating gut function and appetite.Objective To establish the ability of Amarasate®, a bitter supercritical CO2 extract of hops (Humulus lupulus L.) to modify acute energy intake, appetite and hormonal responses and establish a site of action.Design Nineteen healthy-weight (BMI = 23.5 ± 0.3 kg/m2) male volunteers completed a randomised three-treatment, double blind, cross-over study with a 1 week washout between treatments. Overnight-fasted participants were cannulated and provided with a standardised 2 MJ breakfast meal at 0900h. Treatments comprised a vehicle control (Placebo) or 500 mg of hops extract administered in either delayed release capsules (Duodenal) at 1100 h or quick release capsules (Gastric) at 1130 h. Ad libitum energy intake was recorded at an outcome meal (1200 h) and afternoon snack (1400 h), with blood samples taken and subjective ratings of appetite, gastrointestinal discomfort, vitality, meal palatability and mood assessed throughout the day.Results Compared with placebo, both gastric and duodenal treatments significantly reduced (p < 0.05) total ad libitum energy intake by 911 ± 308 kJ and 944 ± 309 kJ, respectively. Both gastric and duodenal treatments significantly increased (p < 0.05) pre-meal ghrelin and post-prandial CCK, GLP-1 and PYY responses while reducing postprandial insulin, GIP and PP secretion with no significant impact on glycemia. In addition, gastric and duodenal treatments produced small but significant (p < 0.05) changes in vitality and gastrointestinal discomfort (e.g. nausea, bloating, abdominal discomfort) with mild-moderate adverse GI symptoms reported in the gastric treatment only. However, no significant treatment effects were observed for any subjective measures of appetite or meal palatability.Conclusion Both gastric and duodenal delivery of Amarasate® modulate the release of hormones involved in appetite and glycaemic regulation, providing a potential “bitter brake” on energy intake in healthy-weight men.Competing Interest StatementEW, MP, KL , CL, KS, JI are employees of The New Zealand Institute for Plant and Food Research Ltd, a New Zealand Government-owned Crown Research Institute, which has a royalty agreement associated with sales of the Amarasate® extract. The authors declare that there is no individual personal financial relationship and they gain no financial incentive or royalty payment outside of salaries for their employment. SDP and HS declare no conflict of interest related to this product. The sponsors had no role in the design of the study, the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.Clinical TrialACTRN12614000434695Funding StatementThis research was funded by the New Zealand Government (NZ Ministry of Business, Innovation & Employment, contract C11X1004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human ethics approval was obtained from the New Zealand Northern B Health and Disability Ethics committee (ref. 14/NTB/25)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData described in the manuscript, code book, and analytic code will be made available upon request(AUC)Area under the curve(T2R)bitter taste receptor(CO2)carbon dioxide(CCK)cholecystokinin(EI)energy intake(EEC)enteroendocrine cell(GI)gastrointestinal(GLP-1)glucagon like peptide-1(GIP)glucose-dependent insulinotropic polypeptide(HbA1c)glycated hemoglobin(hT2R)human bitter taste receptor(LSD)least significant difference(PP)pancreatic polypeptide(PYY)peptide YY(POMS)profile of mood states(VAS)visual analogue scale